Watch BBOT. Know when insiders buy.
One email the day a filing lands. Free.
BBOT
BridgeBio Oncology Therapeutics, Inc.
8.86
−0.12 −1.34%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
51
WATCH · shorts 51
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $710.3MP/E —DIV YIELD —FCF YIELD -21.34%REV TTM —NET INCOME −$182.1MNET CASH —52W 7.12 – 13.73SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$60.2M | −$56.5M | — | -705.20 | −$44.4M | $47K | −$44.4M | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$46.2M | −$42.1M | — | -526.11 | −$35.9M | $24K | −$35.9M | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$43.4M | −$38.8M | — | 2.19 | −$42.2M | $73K | −$42.3M | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$49.2M | −$44.8M | — | -1.03 | −$28.8M | $140K | −$28.9M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$30.1M | −$28.4M | — | -566.46 | −$23.3M | $231K | −$23.5M | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$23.1M | −$22.1M | — | -54.23 | −$19.6M | $162K | −$19.8M | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$21.9M | −$19.7M | — | -833.69 | −$15M | $10K | −$15M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$19.7M | −$17.3M | — | -1562.18 | −$39.3M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$152K | −$21.8M | — | — | −$29K | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$67K | −$15.4M | — | — | −$618K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$145.8M | −$134M | — | -4.30 | −$113.9M | $606K | −$114.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$80.9M | −$74.3M | — | -5756.41 | −$55M | $49K | −$55.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$42K | −$42K | — | — | — | — | — | — | — |
Every number comes from BridgeBio Oncology Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.